Claims data show regorafenib is prescribed earlier than guidelines advise for a good share of patients with advanced GIST, with dosing also varying widely.
|Articles|March 28, 2013
Value-Based Pay Uncommon but Increasing
Advertisement
WASHINGTON -- Value-based payments accounted for 10.9% of all commercial, in-network payments to physicians and hospitals in 2012, up from an estimated 1% to 3% in 2010, a national survey found.
Looking only at physician payments for outpatient services -- for both primary care and specialists -- 6% were value-based, the Catalyst for Payment Reform, a San Francisco-based nonprofit that advocates for better value in healthcare, reported Tuesday.
However, nearly double the percentage, 11%, of all payments to hospitals were value-based,
Read the full story here:
Source: MedPageToday.com
Advertisement
Related to this article
Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.
Activated memory B cells were already enriched at treatment end in the 5 of 21 patients who later cleared HBsAg
Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.
ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.
Each additional hour of nightly CPAP use was associated with 13% lower all-cause mortality risk in a French cohort of adults with sleep apnea.
A 20-year Danish registry study found higher antidepressant and anxiolytic use among women with endometriosis, both before and after diagnosis.
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
3
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
4
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
5